Disease: Respiratory syncytial virus infection

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Maglione

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Vera-Punzano

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Barbas Del Buey

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Community
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Savino

Italy
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Korkmaz

Türkiye
|
2022-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Havlin

Czechia
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination
  • Arexvy

Ferrari

Italy
|
2022-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Raguž

Bosnia and Herzegovina
|
2008-2022
  • Fragile population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

Ehlmaier

Austria
|
2021-2022
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination

Ocana de Sentuary

France
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab